Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants
2상
조기 종료
NCT05584202
| 대상 질환 | SARS-CoV-2 |
|---|
| 임상 단계 | 2상 |
|---|
| 스폰서 | ModernaTX, Inc. |
|---|
| 상태 | 조기 종료 |
|---|
| 참여자 수 | 68 명 |
|---|
| 중재(약물) | mRNA-1273.214 |
|---|
| 시작일 | 2022년 9월 30일 |
|---|
| 완료일 | 2024년 11월 15일 |
|---|
| 결과 공개일 | 2025년 11월 26일 |
|---|
요약
The study evaluated the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273.214 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in infants aged 12 weeks to \< 6 months.
Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) After First Injection
Day 1 up to 7 days after first vaccination (up to Day 8) · Participants
| mRNA-1273.214 5 μg First Injection (Solicited Safety Set) | 23 Participants |
|---|
| mRNA-1273.214 10 μg First Injection (Solicited Safety Set) | 7 Participants |
|---|
| mRNA-1273.214 5 μg First Injection (Solicited Safety Set) | 8 Participants |
|---|
| mRNA-1273.214 10 μg First Injection (Solicited Safety Set) | 3 Participants |
|---|
| mRNA-1273.214 5 μg First Injection (Solicited Safety Set) | 1 Participants |
|---|
| mRNA-1273.214 10 μg First Injection (Solicited Safety Set) | 0 Participants |
|---|
Number of Participants With Solicited Local and Systemic ARs After Second Injection
Day 57 up to 7 days after second vaccination (up to Day 64) · Participants
| mRNA-1273.214 5 μg Second Injection (Solicited Safety Set) | 18 Participants |
|---|
| mRNA-1273.214 10 μg Second Injection (Solicited Safety Set) | 6 Participants |
|---|
| mRNA-1273.214 5 μg Second Injection (Solicited Safety Set) | 7 Participants |
|---|
| mRNA-1273.214 10 μg Second Injection (Solicited Safety Set) | 2 Participants |
|---|
| mRNA-1273.214 5 μg Second Injection (Solicited Safety Set) | 1 Participants |
|---|
| mRNA-1273.214 10 μg Second Injection (Solicited Safety Set) | 0 Participants |
|---|
Number of Participants With Unsolicited Adverse Events (AEs) After Any Injection
Day 1 up to 28 days after any vaccination (up to Day 85) · Participants
| mRNA-1273.214 5 μg (Safety Set) | 24 Participants |
|---|
| mRNA-1273.214 10 μg (Safety Set) | 8 Participants |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.